Professor Mimoun Azzouz | more
SITraN - The University of Sheffield
The University of Sheffield
has a long-standing interest in developing gene therapy approaches for neurodegenerative diseases.
team utilises viral based gene transfer systems both for research and gene therapy applications.
Such viral systems have included lentiviruses and adeno-associated vectors.
research focuses on developing new therapeutic strategies for motor neuron diseases (ALS and SMA) and Parkinson's disease.
also collaborates with other groups looking at new experimental approaches to treatment of Alzheimer's disease and multiple sclerosis.
Members of the team are also investigating molecular pathways and signalling of motor neuron death associated with ALS and SMA.
Professor Azzouz graduated in Biology and Neuroscience from the University of Rabat in 1993.
He obtained a Master in Neuroscience with 1st Class Honours from the University of Marseille in 1994.
In 1997 he was awarded a PhD in Neuropharmacology at the University Louis Pasteur in Strasbourg.
He then worked as post doctoral scientist at the Gene Therapy Center in Lausanne, Switzerland from 1997 to 2000.
He was recruited in 2000 by Oxford BioMedica Ltd as Senior Scientist then appointed as Director of Neurobiology in 2003.
He was also a visiting scientist at Oxford University between 2000 and 2005.
In 2006 he was appointed Professor of Translational Neuroscience at the University of Sheffield.
is currently using his
expertise in neuroscience and gene therapy to develop therapies for motor neuron diseases.
He is a Chair of Translational Neuroscience at the University of Sheffield and formerly Director of Neurobiology at Oxford BioMedica Ltd.
appointment to the Chair of Translational Neuroscience, in 2006, he
assembled an excellent research team and has been successful in attracting an array of scientific funding from prestigious national and international funding bodies.
current research in the newly established gene therapy laboratory is focused on four major objectives:
has an excellent publication track record.
published papers in high profile and prestigious journals such as Nature, Nature Medicine, Nature Neuroscience, Science Translational Medicine.
Azzouz has led the field internationally in developing and evaluating gene therapy approaches using viral vectors, with the potential for exciting new therapeutic approaches in neurodegenerative diseases.
Gene therapy in models of Parkinson's disease (PD) is already translating into human clinical trials and a new SMN replacement strategy is currently entering clinical development for SMA patients.
has been successful in attracting an array of scientific awards including the prestigious ERC Advanced Investigator Award.
This award is a top level EU ad hominem award acknowledging his
pre-eminence in European biomedical research.
Professor Azzouz is advisor for pharmaceutical companies (BioMarin Pharmaceutical Inc, Oxford BioMedica Ltd).
He is member of scientific advisory panel for various funding bodies such as the Medical Research Council (MRC), the French Muscular Dystrophy Association and The Research Council of Norway.
Professor Azzouz's research
is funded by the Medical Research Council
, Jennifer Trust, EPSRC, AFM, SMA Europe, ERC Advanced Award and MRC DPFS